Literature DB >> 2795716

Expression of infectious woodchuck hepatitis virus in murine and avian fibroblasts.

C Seeger1, B Baldwin, B C Tennant.   

Abstract

The liver is the primary site for replication of the hepadnavirus genome. We asked whether the posttranscriptional phase of the viral replication cycle would depend on hepatocyte-specific functions. For this purpose, we assayed a previously constructed chimera between sequences of the cytomegalovirus immediate-early promoter-enhancer region and woodchuck hepatitis virus (WHV) (C. Seeger and J. Maragos, J. Virol. 63:1907-1915, 1989) for its ability to direct the synthesis of infectious WHV in hepatoma cells and in murine and avian fibroblast cells. Viruslike particles containing WHV DNA were produced transiently in transfected hepatoma cells and in fibroblasts. Inoculation of woodchucks with culture medium from hepatoma cells or fibroblasts transfected with viral DNA led to productive WHV infection, as observed following infection of woodchucks with serum from WHV-infected animals. These results demonstrate that posttranscriptional events of the hepadnavirus replication cycle are not dependent on hepatocyte-specific functions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2795716      PMCID: PMC251100     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA.

Authors:  C Sureau; J L Romet-Lemonne; J I Mullins; M Essex
Journal:  Cell       Date:  1986-10-10       Impact factor: 41.582

2.  Molecular analysis of the function of direct repeats and a polypurine tract for plus-strand DNA priming in woodchuck hepatitis virus.

Authors:  C Seeger; J Maragos
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

3.  Structural analysis of the major immediate early gene of human cytomegalovirus.

Authors:  R M Stenberg; D R Thomsen; M F Stinski
Journal:  J Virol       Date:  1984-01       Impact factor: 5.103

4.  Core and E antigen synthesis in rodent cells transformed with hepatitis B virus DNA is associated with greater than genome length viral messenger RNAs.

Authors:  N M Gough
Journal:  J Mol Biol       Date:  1983-04-25       Impact factor: 5.469

5.  Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line.

Authors:  D P Aden; A Fogel; S Plotkin; I Damjanov; B B Knowles
Journal:  Nature       Date:  1979-12-06       Impact factor: 49.962

6.  Novel RNA family structure of hepatitis B virus expressed in human cells, using a helper-free adenovirus vector.

Authors:  I Saito; Y Oya; H Shimojo
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

7.  Mapping the major transcripts of ground squirrel hepatitis virus: the presumptive template for reverse transcriptase is terminally redundant.

Authors:  G H Enders; D Ganem; H Varmus
Journal:  Cell       Date:  1985-08       Impact factor: 41.582

8.  In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus.

Authors:  J S Tuttleman; J C Pugh; J W Summers
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

9.  Nucleotide sequence of a cloned woodchuck hepatitis virus genome: evolutional relationship between hepadnaviruses.

Authors:  K Kodama; N Ogasawara; H Yoshikawa; S Murakami
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

10.  Biochemical and genetic evidence for the hepatitis B virus replication strategy.

Authors:  C Seeger; D Ganem; H E Varmus
Journal:  Science       Date:  1986-04-25       Impact factor: 47.728

View more
  15 in total

1.  Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine.

Authors:  T Zhou; J Saputelli; C E Aldrich; M Deslauriers; L D Condreay; W S Mason
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Improved method for rapid and efficient determination of genome replication and protein expression of clinical hepatitis B virus isolates.

Authors:  Yanli Qin; Jiming Zhang; Tamako Garcia; Kiyoaki Ito; Danielle Gutelius; Jisu Li; Jack Wands; Shuping Tong
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

3.  Cellular factors controlling the activity of woodchuck hepatitis virus enhancer II.

Authors:  K Ueda; Y Wei; D Ganem
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

Review 4.  Origins and Evolution of Hepatitis B Virus and Hepatitis D Virus.

Authors:  Margaret Littlejohn; Stephen Locarnini; Lilly Yuen
Journal:  Cold Spring Harb Perspect Med       Date:  2016-01-04       Impact factor: 6.915

5.  Efficient duck hepatitis B virus production by an avian liver tumor cell line.

Authors:  L D Condreay; C E Aldrich; L Coates; W S Mason; T T Wu
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

6.  Woodchuck hepatitis virus X protein is required for viral infection in vivo.

Authors:  F Zoulim; J Saputelli; C Seeger
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  Nucleotide sequence stability of the genome of hepatitis delta virus.

Authors:  H J Netter; T T Wu; M Bockol; A Cywinski; W S Ryu; B C Tennant; J M Taylor
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

8.  Primary human hepatocytes are susceptible to infection by hepatitis delta virus assembled with envelope proteins of woodchuck hepatitis virus.

Authors:  Severin Gudima; Yiping He; Ning Chai; Volker Bruss; Stephan Urban; William Mason; John Taylor
Journal:  J Virol       Date:  2008-05-21       Impact factor: 5.103

9.  Hepatitis B virus X protein is not central to the viral life cycle in vitro.

Authors:  H E Blum; Z S Zhang; E Galun; F von Weizsäcker; B Garner; T J Liang; J R Wands
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

10.  In vivo effects of mutations in woodchuck hepatitis virus enhancer II.

Authors:  Y Wei; B Tennant; D Ganem
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.